FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.?Using our proprietary Gene Traffic Control platform, we are developing a broad pipeline of product candidates that target genetically determined dependencies within the chromatin regulatory system.?

$11.15  -0.12 (-1.07%)
As of 12/03/2021 15:59:33 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/22/2020
Outstanding shares:  37,091,588
Average volume:  50,485
Market cap:   $418,022,197
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    344174107
ISIN:        US3441741077
Sedol:      BMF7DT9

---

Valuation   (See tab for details)

---

PE ratio:   -4.41
PB ratio:   5.05
PS ratio:   689.52
Return on equity:   -89.21%
Net income %:   -11,916.81%